Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.

Modified nanoprecipitation method was used for improved incorporation of hydrophilic drug (irinotecan hydrochloride) into the PLGA/PEO-PPO-PEO blended and blended/adsorbed nanoparticles. One factor at a time (OFAT) variation experiments were conducted in order to determine key formulation factors (concentration and volume of drug solution, evaporation rate and PLGA/PEO-PPO-PEO ratio) influencing nanoparticle properties (particle size and size distribution, encapsulation efficiency, drug content, zeta potential, drug dissolution rate, as well as protein binding capacity). The insight into in vivo behavior of prepared nanoparticles and their potential for effective anticancer treatment was gained by performing biodistribution and cell culture studies as part of OFAT experiments. The mean particle size, mainly dependent upon PLGA/PEO-PPO-PEO ratio, was in the range of 112-125 nm, with narrow unimodal distribution (PDI∼0.1). Encapsulation efficiency (32-63%) was impacted by evaporation rate and PLGA/PEO-PPO-PEO ratio. Drug content (0.2-1.51%) and controlled release properties were related to the influence of all tested formulation factors. Structural information for the studied nanoparticles was obtained using DSC and FT-IR spectroscopy. Zeta potential values indicated that presence of PEO-PPO-PEO in the formulations shielded the high surface negative charge of PLGA. PEO-PPO-PEO surface coverage of PLGA/PEO-PPO-PEO blended as well as blended/adsorbed nanoparticles depended upon amount of used PEO-PPO-PEO during preparation procedure and was related to the protein resistant characteristics of nanoparticles. Results from in vivo studies evidenced prolonged blood circulation time of the prepared nanoparticles, while cell culture studies indicated higher in vitro bioefficacy compared to free drug. Performed experiments defined possible design space and justified further optimization of formulation using experimental design studies.

[1]  S. Lesieur,et al.  Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. , 2007, International journal of pharmaceutics.

[2]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[3]  M. Ulbricht,et al.  Size-selective protein adsorption to polystyrene surfaces by self-assembled grafted poly(ethylene glycols) with varied chain lengths. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[4]  A. Durand,et al.  Polysaccharide-covered nanoparticles prepared by nanoprecipitation , 2011 .

[5]  T. Cosgrove,et al.  Adsorption studies of polyethers , 1999 .

[6]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[7]  L. Koopal,et al.  The effect of polyethylene oxide molecular weight on determination of its concentration in aqueous solutions. , 1982, Talanta.

[8]  M. Whitmore,et al.  Theory of the structure of adsorbed block copolymers: Detailed comparison with experiment , 1995 .

[9]  S. Davis,et al.  Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[10]  M. R. Kumar,et al.  PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. , 2008, Journal of pharmaceutical sciences.

[11]  H. Fessi,et al.  Physicochemical Parameters Associated with Nanoparticle Formation in the Salting-Out, Emulsification-Diffusion, and Nanoprecipitation Methods , 2004, Pharmaceutical Research.

[12]  T. Ehtezazi,et al.  Defining the drug incorporation properties of PLA-PEG nanoparticles. , 2000, International journal of pharmaceutics.

[13]  Liangfang Zhang,et al.  Therapeutic nanoparticles to combat cancer drug resistance. , 2009, Current drug metabolism.

[14]  Shaofei Xie,et al.  DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles , 2010, The AAPS Journal.

[15]  K. Sawant,et al.  Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. , 2011, Acta biomaterialia.

[16]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  C. Rhodes,et al.  Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. , 1998, Drug development and industrial pharmacy.

[18]  P. Legrand,et al.  Polyester-Poly(Ethylene Glycol) Nanoparticles Loaded with the Pure Antiestrogen RU 58668: Physicochemical and Opsonization Properties , 2003, Pharmaceutical Research.

[19]  M. Morishita,et al.  Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. , 1999, Drug development and industrial pharmacy.

[20]  B Ruozi,et al.  PLA/PLGA nanoparticles for sustained release of docetaxel. , 2006, International journal of pharmaceutics.

[21]  Kinam Park,et al.  Control of encapsulation efficiency and initial burst in polymeric microparticle systems , 2004, Archives of pharmacal research.

[22]  S. K. Ghosal,et al.  Preparation, characterization, and biodistribution of letrozole loaded PLGA nanoparticles in Ehrlich Ascites tumor bearing mice. , 2010, International journal of pharmaceutics.

[23]  Asuman Bozkir,et al.  Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. , 2005, Farmaco.

[24]  Martyn C. Davies,et al.  In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers , 1997 .

[25]  G. Yordanov,et al.  Entrapment of epirubicin in poly(butyl cyanoacrylate) colloidal nanospheres by nanoprecipitation: formulation development and in vitro studies on cancer cell lines. , 2012, Colloids and surfaces. B, Biointerfaces.

[26]  Rubiana M Mainardes,et al.  PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. , 2005, International journal of pharmaceutics.

[27]  V. C. Malshe,et al.  Nanoparticles of Polyethylene Sebacate: A New Biodegradable Polymer , 2009, AAPS PharmSciTech.

[28]  M. Gremião,et al.  Thermoanalytical study of praziquantel-loaded PLGA nanoparticles , 2006 .

[29]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[30]  A. Elaissari,et al.  Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods critical comparison. , 2011, Advances in colloid and interface science.

[31]  S. Surrey,et al.  Construction of human gene libraries from small amounts of peripheral blood: analysis of beta-like globin genes. , 1982, Hemoglobin.

[32]  M. J. Santander-Ortega,et al.  Stability and physicochemical characteristics of PLGA, PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: A comparative study , 2007 .

[33]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[34]  M. Espina,et al.  Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. , 2006, Journal of pharmaceutical sciences.

[35]  Xiangrong Song,et al.  Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[36]  H. Maeta,et al.  Grain size measurement of nanocrystalline gold by X-ray diffraction method , 1999 .

[37]  D. Lyster,et al.  Evaluation of formamidine sulfinic acid and other reducing agents for use in the preparation of Tc-99m labeled radiopharmaceuticals. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  D. Marchisio,et al.  Preparation of polymer nanoparticles loaded with doxorubicin for controlled drug delivery , 2011 .

[39]  S. Schwendeman,et al.  Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[40]  S. Uzzau,et al.  Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies , 2011, Nanoscale research letters.

[41]  J. M. Marchetti,et al.  Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. , 2006, International journal of pharmaceutics.

[42]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[43]  Xiaoying Wang,et al.  Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the "ouzo region" upon drug loading. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[45]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[46]  S. Davis,et al.  PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[47]  Paula T. Hammond,et al.  Mixed micelles self-assembled from block copolymers for drug delivery , 2011 .

[48]  D. Fischer,et al.  Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  M. J. Santander-Ortega,et al.  Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. , 2006, Journal of colloid and interface science.

[50]  V. H. Lee,et al.  Influence of Preparation Conditions on Acyclovir-Loaded Poly-d,l-Lactic Acid Nanospheres and Effect of PEG Coating on Ocular Drug Bioavailability , 2003, Pharmaceutical Research.

[51]  Y. I. Kim,et al.  Preparation and characterization of nanoparticles containing an antihypertensive agent. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[52]  S. Schwendeman,et al.  Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly(D,L-lactide-co-glycolide) microspheres. , 2004, Biomaterials.

[53]  R. Tsay,et al.  Adsorption of PEO–PPO–PEO triblock copolymers on a gold surface , 2011 .

[54]  P. D'Arpa,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.

[55]  S. Feng,et al.  Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[56]  M. Alonso,et al.  Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[57]  M. Radwan In Vitro Evaluation of Polyisobutylcyanoacrylate Nanoparticles as a Controlled Drug Carrier for Theophylline , 1995 .

[58]  H. Chung,et al.  Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[59]  D. Scudiero,et al.  Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. , 1991, Cancer research.

[60]  T. Cosgrove,et al.  Adsorption studies of polyethers Part 1. Adsorption onto hydrophobic surfaces , 1998 .

[61]  Ilia Fishbein,et al.  Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[62]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[63]  D. Quintanar-Guerrero,et al.  Preparation and characterization of triclosan nanoparticles for periodontal treatment. , 2005, International journal of pharmaceutics.

[64]  P. Stroeve,et al.  Adsorption and Desorption of PEO−PPO−PEO Triblock Copolymers on a Self-Assembled Hydrophobic Surface , 2003 .

[65]  J. Chalmers,et al.  Spectra–Structure Correlations: Polymer Spectra , 2006 .